To Deliver Necessary Drugs to Patients - Pharmaceutical Manufacturers Association Urges Government to Strengthen Support for Unapproved Drugs
There are "drugs that are not yet available in Japan, but have been approved overseas. This is called "drug loss" and is a problem especially in the fields of pediatrics and rare diseases. The Pharmaceutical Manufacturers Association of Japan (PMAJ), from the standpoint of the business community, is requesting the government to provide more support for the government's efforts to make such drugs available in Japan. There is a system under which the government publicly solicits applications for drugs for which development companies cannot be found, but there is a lack of information and concerns about profitability for companies to take on these projects, and the hurdles are high in the field.
This time, Yuji Kashiwa, Chairman of the Pharmaceutical Affairs Committee, Yukiko Sakakibara, leader of the Industrial Policy Committee's Drug Licensing Task Force, and other related committee members called for "more effective support measures that focus on the entire process from development to delivery to patients," which was introduced in an interview article.
This article was published in Nikkan Yakugyo on July 15, 2025 [license number 20250715_02]. Jippo Co., Ltd. has granted permission for use of the article.